P
IOVA icon

&Partners’s Iovance Biotherapeutics IOVA Stock Holding History

&Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.1K Buy
+11,075
New +$42.1K ﹤0.01% 2494

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

&Partners's IOVA Position: Q2 2026 in Review

&Partners opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 11,075 shares worth $46.1K. The stake represents ﹤0.01% of the portfolio and ranks #2494 among its holdings.

292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • &Partners held 11,075 shares of Iovance Biotherapeutics worth $46.1K as of Q2 2026.
  • Iovance Biotherapeutics was a new &Partners position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2494 holding.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.